How does FDG work in a PET scan?

How does FDG work in a PET scan?

• A. It mimics glucose and accumulates in high-metabolism areas
• B. It binds to oxygenated blood cells
• C. It provides contrast for soft tissue imaging
• D. It targets specific cancer markers directly

Answer: (A)

FDG, or fluorodeoxyglucose, plays a crucial role in PET scans by closely mimicking glucose, which is a primary energy source for cells, particularly in high-metabolism areas such as tumors. When FDG is injected into the body, it is taken up by cells in a manner similar to glucose. This uptake is significantly higher in areas with increased metabolic activity, such as cancerous tissues, because they consume glucose at higher rates compared to normal tissues. Once inside the cell, FDG is phosphorylated to FDG-6-phosphate, which is trapped in the cells and cannot undergo further metabolism. This allows PET imaging to highlight areas of enhanced glucose metabolism, which is indicative of disease processes, particularly in oncology for cancer detection and monitoring. The other choices do not accurately represent the mechanism of FDG in PET imaging. FDG does not bind to oxygenated blood cells, provide contrast for soft tissue imaging in the way that traditional contrast agents (like those used in CT) do, nor does it specifically target cancer markers directly; its usefulness arises from its uptake related to metabolic activity rather than specific receptor binding.

FDG, or fluorodeoxyglucose, plays a crucial role in PET scans by closely mimicking glucose, which is a primary energy source for cells, particularly in high-metabolism areas such as tumors. When FDG is injected into the body, it is taken up by cells in a manner similar to glucose. This uptake is significantly higher in areas with increased metabolic activity, such as cancerous tissues, because they consume glucose at higher rates compared to normal tissues.

Once inside the cell, FDG is phosphorylated to FDG-6-phosphate, which is trapped in the cells and cannot undergo further metabolism. This allows PET imaging to highlight areas of enhanced glucose metabolism, which is indicative of disease processes, particularly in oncology for cancer detection and monitoring.

The other choices do not accurately represent the mechanism of FDG in PET imaging. FDG does not bind to oxygenated blood cells, provide contrast for soft tissue imaging in the way that traditional contrast agents (like those used in CT) do, nor does it specifically target cancer markers directly; its usefulness arises from its uptake related to metabolic activity rather than specific receptor binding.